NICE recommends Somatropin for children with growth failure

March 18th, 2010 - London - Today, the National Institute for Health and Clinical Excellence (NICE) has recommended Pfizer's Genotropin® as one of several somatropin treatment options for children with growth failure. This guidance was published in NICE's Final Appraisal Determination (FAD) for the use of recombinant human growth hormone (rhGH) in children with growth failure1.

Dr John Porter, Paediatric Endocrinologist and Speciality Medical Team Lead at Pfizer Limited comments: "We welcome NICE's final guidance, which will provide clinicians with the choice to prescribe the most appropriate treatment based on individual patient need and the likelihood of adherence to treatment. We will continue to work with endocrine healthcare professionals to deliver a range of support services, materials and devices to help ensure patients adhere to their treatment."

As part of the NICE appraisal, safety and efficacy data from the International Growth Database (KIGS), developed in collaboration between clinicians and Pfizer was reviewed. Launched in 1987, KIGS has enrolled more than 60,000 patients with growth deficiencies from more than 50 countries2. The data collected on these patients has become a major source of information for growth disorders and treatments.

The FAD states that somatropin (including Pfizer's medicine Genotropin®) is recommended as a treatment option for children with growth failure associated with any of the following conditions including growth hormone deficiency; Turner syndrome; Prader-Willi syndrome; chronic renal insufficiency and being born small for gestational age with subsequent growth failure at 4 years of age or later.

Notes to Editors:

About Genotropin
Genotropin is an exact copy of the natural growth hormone made by the body. It is manufactured by Pfizer using recombinant DNA technology and produces the effect of naturally occurring growth hormone (GH). The therapy in children aims to stimulates growth in cases where the child does not grow at the same rate as other children of the same age. Genotropin has been in the market for more than 20 years in the UK and there are more than 60,0003; children and 11,0004; adults worldwide that continue to receive the benefits of this important and effective treatment option.

About KIGS

Since its inception in 1987, KIGS (Pfizer International Growth Database) has established itself as a major pharmacoepidemiological survey investigating growth hormone treatment in children with short stature. Today more than 60,000 patients from more than 50 countries have been enrolled in KIGS and a considerable number of them have been followed to final height. Over the years, KIGS has become a major source of documentation of growth disorders and their treatment with recombinant GH.     

Pfizer: Working Together for a Healthier World™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.

Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

1National Institute for Health and Clinical Excellence. Final Appraisal Determination. Human growth hormone (somatropin) for the treatment of growth failure in children (Review of NICE technology appraisal guidance 42); March 2010 [Internet]. Sollentuna: KIGS, Pfizer Health, c2008 [cited 2010 Mar 18]. Available from:
3Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 Years of KIGS. KIGS: Structure and Organization. Basel, Karger, 2007, pp 1- 5.
4Gutièrrez LP et al., Pharmacoepidemiology and Drug Safety 2008; 17:90-102.